PRT062607 HCl

featured

WARNING: This product is for research use only, not for human or veterinary use.

Description:PRT062607, also known as P505-15, PRT2607, PRT62607, and BIIB057, is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases. P505-15 successfully inhibited SYK-mediated B-cell receptor signaling and decreased cell viability in NHL and CLL.

Price and Availability

PRT062607 HCl (P505-15 HCl), purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and SDS documents are available in one week after order is received.

Chemical Structure

Theoretical Analysis

MedKoo Cat#: 406272Name: PRT062607 HClCAS#: 1370261-97-4 (HCl)Chemical Formula: C19H24ClN9OExact Mass: 393.20256Molecular Weight: 429.913Elemental Analysis: C, 53.08; H, 5.63; Cl, 8.25; N, 29.32; O, 3.72

Related CAS #:1370261-97-4 (HCl)1370261-96-3 (free base)

Synonym:PRT2607; PRT-2607; PRT 2607; PRT062607; PRT-062607; PRT 062607; BIIB057; BIIB-057; BIIB 057; P-505-15; P 505-15; P505-15; P-50515; P 50515; P50515

IUPAC/Chemical Name:4-((3-(2H-1,2,3-triazol-2-yl)phenyl)amino)-2-(((1R,2S)-2-aminocyclohexyl)amino)pyrimidine-5-carboxamide hydrochloride

InChi Key:RMNLLPXCNDZJMJ-IDVLALEDSA-N

InChi Code:InChI=1S/C19H23N9O.ClH/c20-15-6-1-2-7-16(15)26-19-22-11-14(17(21)29)18(27-19)25-12-4-3-5-13(10-12)28-23-8-9-24-28;/h3-5,8-11,15-16H,1-2,6-7,20H2,(H2,21,29)(H2,22,25,26,27);1H/t15-,16+;/m0./s1

SMILES Code:O=C(C1=CN=C(N[C@H]2[C@@H](N)CCCC2)N=C1NC3=CC=CC(N4N=CC=N4)=C3)N.[H]Cl

Technical Data

Additional Information

References

1: Spurgeon SE, Coffey G, Fletcher LB, Burke R, TynerJW, Druker BJ, Betz A, DeGuzman F, Pak Y, Baker D, Pandey A, Hollenbach SJ, Sinha U, LoriauxMM. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signalingand function in vitro and in vivo and augments the activity of fludarabinein chronic lymphocytic leukemia. J Pharmacol Exp Ther. 2013 Feb;344(2):378-87. doi: 10.1124/jpet.112.200832. Epub 2012 Dec 7. PubMed PMID: 23220742; PubMedCentral PMCID: PMC3558816.

2: Hoellenriegel J, Coffey GP, Sinha U, Pandey A, Sivina M, Ferrajoli A,Ravandi  F, Wierda WG, O"Brien S, Keating MJ, Burger JA. Selective, novel spleentyrosine  kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cellactivation and migration. Leukemia. 2012 Jul;26(7):1576-83. doi:10.1038/leu.2012.24. Epub 2012 Feb 7. PubMed PMID: 22362000.

3: Coffey G, DeGuzman F, Inagaki M, Pak Y, Delaney SM, Ives D, Betz A,Jia ZJ, Pandey A, Baker D, Hollenbach SJ, Phillips DR, Sinha U. Specificinhibition of spleen tyrosine kinase suppresses leukocyte immune function andinflammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ther. 2012 Feb;340(2):350-9. doi: 10.1124/jpet.111.188441. Epub 2011 Oct 31. PubMedPMID: 22040680.